INOZYME PHARMA INC. -

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

12 Mar 2024 08:30:16 By Nasdaq GlobeNewswire

Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

26 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Feb 2024 08:30:48 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Dec 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Participate in Upcoming Investor Conferences

09 Nov 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

07 Nov 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Nov 2023 16:15:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023

26 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions

10 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

06 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

26 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023

20 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

05 Sep 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

08 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock

01 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock

27 Jul 2023 23:20:15 By Nasdaq GlobeNewswire

Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock

27 Jul 2023 16:33:08 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

26 Jul 2023 07:30:00 By Nasdaq GlobeNewswire